Compounded semaglutide vs Ozempic: they are not the same product. Ozempic is FDA-approved, made to tested standards and sold in pens dosed in milligrams. Compounded semaglutide is mixed by pharmacies, is not FDA-approved, is sometimes made from salt forms FDA calls different active ingredients, and comes in vials that have led to dosing errors.[1] Since the semaglutide shortage ended on February 21, 2025, compounding copies has been sharply restricted.[2]
For how semaglutide works and its approved uses, see our semaglutide profile.
Side-by-side comparison
| Ozempic (and Wegovy) | Compounded semaglutide | |
|---|---|---|
| FDA approval | Approved[8] | Not approved[1] |
| Active ingredient | Semaglutide, as in the approved application | Semaglutide base, or sometimes sodium or acetate salts[1] |
| Quality review | FDA reviews manufacturing before and after approval | Not reviewed by FDA before sale[1] |
| Form | Prefilled pen, dose in mg[8] | Usually vial and syringe; also drops and tablets[6] |
| Added ingredients | None | Sometimes B12, glycine, niacinamide and others[6] |
| Clinical trial evidence | Large randomized trials | No randomized trials |
| Boxed warning and label | Full prescribing information[8] | No FDA-approved label |
Is the ingredient the same?
Ozempic and Wegovy contain semaglutide made and tested to the specifications in Novo Nordisk’s approved applications. Compounded products may differ in three ways.
- Salt forms: FDA says some compounders use semaglutide sodium or semaglutide acetate. These are different active ingredients from the approved drugs, and FDA says it is not aware of any lawful basis for compounding with them.[1]
- Source and purity: compounders buy semaglutide as a bulk powder. FDA does not review the finished product for identity, strength or purity before sale.[1]
- Formulation: a 2026 review found many compounded products used sublingual drops, dissolving tablets or added ingredients not found in any approved product, with little information on stability or storage.[6]
FDA has also said companies cannot claim compounded products are generic versions of approved drugs, the same as them, or use the same active ingredient.[3]
Dosing errors: the biggest practical risk
Ozempic pens deliver fixed doses in milligrams: 0.25, 0.5, 1 or 2 mg.[8] Compounded semaglutide usually comes in a multi-dose vial. The patient draws a dose into a syringe often marked in units, and the right number of units depends on the vial’s concentration.
FDA has received reports of adverse events from these errors, some requiring hospitalization. Some came from patients measuring wrongly, others from clinicians miscalculating doses.[1]
A poison control center case series described three patients who had nausea, vomiting and abdominal pain lasting days after compounded semaglutide errors. Two had taken 10 times the intended dose. One received a vial and syringes with no pharmacist counseling, and one was confused by doses in milliliters, units and milligrams.[5]
Storage and shelf life
Approved pens come with tested storage instructions. Before first use, Ozempic pens are kept in the refrigerator. After first use, a pen can be stored for 56 days at room temperature (59°F to 86°F) or in the refrigerator, must not be frozen, and should be kept away from heat and sunlight.[8]
Compounded products vary. In the 2026 review of compounded semaglutide and tirzepatide products, only 28% listed preferred storage conditions and only 18% listed both a beyond-use date and storage conditions.[6] Without that information, it is hard to know how long a vial stays at full strength once opened. For general advice, see our GLP-1 storage guide.
Questions to ask if you use compounded semaglutide
- Which form of semaglutide is it? Ask whether it is semaglutide base or a salt such as semaglutide sodium or acetate.[1]
- What is the concentration? Get the mg per mL in writing and the exact syringe marking for your dose.[1]
- What else is in it? Check for added vitamins or other ingredients.[6]
- What is the beyond-use date, and how should I store it?[6]
- Why was compounded semaglutide chosen over the approved product? Under FDA policy, a prescriber must document a significant clinical difference for you as an individual patient.[2]
- How do I report a problem? Side effects from any drug, including compounded drugs, can be reported to FDA’s MedWatch program.
Side effects and adverse event reports
The expected side effects are the same as for approved semaglutide: mainly nausea, vomiting, diarrhea and constipation.[8] The extra risks come from dose errors, uncertain strength and unknown quality.
As of May 31, 2026, FDA had received 990 adverse event reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide, and it says these are likely undercounted.[1] FDA has also reported people needing care after taking doses above the labeled amounts.[1]
The American Diabetes Association has raised safety, quality and efficacy concerns about compounded GLP-1 products.[7]
Does compounded semaglutide work?
There are no randomized trials of compounded semaglutide. One retrospective study of 94 people using a compounded semaglutide-B12 injection at a commercial wellness program found 4.6% average weight loss at 3 months, with no comparison group.[9] Approved semaglutide 2.4 mg produced 14.9% average loss over 68 weeks in a placebo-controlled trial.[10] The two cannot be compared directly. See semaglutide weight loss results for the full trial data.
Legal status after the shortage
| Date | What changed |
|---|---|
| Feb 21, 2025 | FDA declared the semaglutide injection shortage resolved[2] |
| Apr 2025 | Grace period ended for state-licensed (503A) pharmacies compounding copies[2] |
| May 22, 2025 | Grace period ended for outsourcing facilities (503B)[2] |
| Feb 6, 2026 | FDA announced plans to restrict GLP-1 ingredients for non-approved compounded drugs and act on misleading marketing[3] |
| Apr 30, 2026 | FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list[4] |
Under current policy, a 503A pharmacy generally may not make a drug that is essentially a copy of Ozempic or Wegovy. The main exception is when a prescriber determines and documents that a change produces a significant difference for an identified individual patient.[2] The April 2026 bulks proposal was open for comment until June 29, 2026, and FDA said it would consider comments before a final decision.[4]
Cost and access to approved semaglutide
Cost was the main reason many people used compounded semaglutide. Manufacturer self-pay programs and savings cards now offer lower prices on approved products for eligible patients. See Ozempic cost without insurance, semaglutide cost and how to get semaglutide without insurance.
The bottom line
Compounded semaglutide is not a generic Ozempic. It is not FDA-approved, may use a different salt form, is easy to mis-dose from a vial, and is now tightly restricted. If you use or are considering it, discuss the risks with your prescriber and pharmacist. For a related look at add-ins, see compounded semaglutide with B12, and for tirzepatide, compounded tirzepatide.
